February 18, 2020

Ren e Aguiar-Lucander
Chief Executive Officer
Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22
Stockholm, Sweden

       Re: Calliditas Therapeutics AB
           Amendment No. 1 to Draft Registration Statement on Form F-1
           Submitted February 4, 2020
           CIK No. 0001795579

Dear Ms. Aguiar-Lucander:

      We have reviewed your amended draft registration statement and have the
following
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comments apply to your facts and circumstances
or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to these comments
and your
amended draft registration statement or filed registration statement, we may
have additional
comments. Our references to prior comments are to comments in our January 10,
2020 letter.

Amendment No. 1 to Draft Registration Statement on Form F-1

Global Offering, page 8

1.     With respect to the common shares that will be issued in the European
private placement,
       please disclose in an appropriate location in your prospectus if, when
and where such
       shares will be eligible to trade.
2.     If the underwriters could conduct transactions during the global
offering that stabilizes,
       maintains, or otherwise affects the market price of your common shares
on Nasdaq
       Stockholm, please revise your "Underwriting" section to make that clear
and to disclose
       when those transactions could be discontinued. Also, if any stabilizing
by the
       underwriters is to begin on Nasdaq Stockholm before the effective date
of the registration
 Ren e Aguiar-Lucander
Calliditas Therapeutics AB
February 18, 2020
Page 2
      statement, disclose the amount of securities bought, the prices at which
they were bought
      and the period within which they were bought. Please also confirm that
the prospectus
      you file under Securities Act Rule 424(b), or a post-effective amendment,
will include
      information on the stabilizing transactions that took place before the
determination of the
      public offering price of the securities offered in your global offering.
3.    Please revise the last bullet point on page 9 to disclose, if true, that
the number of your
      securities to be outstanding after the global offering assumes no
exercise by the
      underwriters of their option to purchase additional ordinary shares in
the European private
      placement.
Budenofalk for Autoimmune Hepatitis, page 106

4.    We note your response to comment 8. However, given that Budenofalk for
Autoimmune
      Hepatitis is one of the two programs highlighted in your pipeline table,
your previous
      statements that the agreement is an opportunity to accelerate your
development program
      in AIH, and the orphan drug designation it appears the program is
material to your
      operations. We note your statements that there has been no clinical
development in the
      US but also note the statements in your August 2019 press release that
you aim to
      leverage the clinical trial data from Dr. Falk to support your
discussions with the FDA and
      to accelerate your development program in AIH. Please file the agreement
and disclose
      the material terms. Alternatively, revise your summary to remove the
program from the
      pipeline table and provide additional disclosure emphasizing the nature
of your early stage
      upcoming discussions with the FDA.
Patents, page 109

5.    We note your response to prior comment 11. If third parties could compete
with you by
      developing another formulation for the oral delivery of budesonide or
other corticosteroids
      to the ileum that would not infringe upon your patents, please revise to
make that clear
      and include appropriate risk factor disclosure.
       You may contact Sasha Parikh at (202) 551-3627 or Lynn Dicker at (202)
551-3616 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Tim Buchmiller at (202) 551-3635 or Suzanne Hayes at (202) 551-3675
with any other
questions.



                                                            Sincerely,
FirstName LastNameRen e Aguiar-Lucander
                                                            Division of
Corporation Finance
Comapany NameCalliditas Therapeutics AB
                                                            Office of Life
Sciences
February 18, 2020 Page 2
cc:       Michael Rosenberg, Esq.
FirstName LastName